Register

Login

+
  • View all news
  • Vets news
  • Vet Nursing news
  • Business news
  • + More
    • Videos
    • Podcasts
  • View all clinical
  • Small animal
  • Livestock
  • Equine
  • Exotics
  • Vet Times jobs home
  • All Jobs
  • Your ideal job
  • Post a job
  • Career Advice
  • Students
About
Contact Us
For Advertisers
NewsClinicalJobs

Vets

All Vets newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Vet Nursing

All Vet Nursing newsSmall animalLivestockEquineExoticWork and well-beingOpinion

Business

All Business newsHuman resourcesBig 6SustainabilityFinanceDigitalPractice profilesPractice developments

+ More

VideosPodcasts

The latest veterinary news, delivered straight to your inbox.

Choose which topics you want to hear about and how often.

About

Advertise with us

Recruitment

Contact us

Vets

All Vets news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Vet Nursing

All Vet Nursing news

Small animal

Livestock

Equine

Exotic

Work and well-being

Opinion

Business

All Business news

Human resources

Big 6

Sustainability

Finance

Digital

Practice profiles

Practice developments

Clinical

All Clinical content

Small animal

Livestock

Equine

Exotics

Jobs

All Jobs content

All Jobs

Your ideal job

Post a job

Career Advice

Students

More

All More content

Videos

Podcasts


Terms and conditions

Complaints policy

Cookie policy

Privacy policy

© Veterinary Business Development Ltd 2025

IPSO_regulated

15 Mar 2017

Specials could change way vets treat horses

The granting of the UK’s first sterile Manufacturer’s Specials Authorisation by the VMD has the potential to change the way equine vets here manage horses, according to BEVA.

author_img

David Woodmansey

Job Title



Specials could change way vets treat horses

The granting of the UK’s first sterile Manufacturer’s Specials Authorisation (ManSA) by the VMD has the potential to change the way equine vets here manage horses, according to BEVA.

Bova Specials UK Limited has become the first in the UK to obtain specific veterinary authorisation to manufacture sterile specials, though some human health companies are able to supply under licence from the Medicines and Healthcare Products Regulatory Agency.

Mark Bowen
“I think it could be very big,” said BEVA senior vice-president Mark Bowen of the specials market.

The Australian-based parent company, Bova Compounding, is a specialist in veterinary compounding.

Mark Bowen, BEVA senior vice-president and professor of veterinary internal medicine at The University of Nottingham, said: “My understanding is Bova UK is the first specials company with a licence to produce IV specials.

“They will be in a position to meet demand for veterinary products where big pharma essentially can’t make these drugs financially viable as commercial products. I think it could be very big.”

‘Gap in the market’

He continued: “BEVA is very supportive of the concept of specials manufacturers where it fills a gap in the market, because veterinary availability of equine medicines is so limited by the fact it is such a small market, though we wouldn’t say we support any individual company.

“Our challenge in the equine market is if we don’t have the drugs – we end up crushing up human tablets. We now have a new route to accessing them, which will be through specials manufacturers.

“I think some of the products this will make more available to equine vets will revolutionise the way we treat horses. Well, perhaps ‘revolutionise’ is a bit strong, but it will certainly change and improve the way we manage horses.”

ManSA

The VMD confirmed Bova has been granted a ManSA, which permits the holder to manufacture products under the cascade and will appear on its register when it is next updated.

Five holders of a VMD ManSA permit exist in the UK.

  • Read the full story in March 20 issue of Veterinary Times.